SIRPA and cancer: In addition to the CD47/SIRPα cascade, CD40 agonists re-educate TAMs into M1 macrophages to restore cancer immune surveillance (191), and the combination therapy of anti-PD1/PD-L1 and anti-CD40 also enhances anti-tumor efficacy (191, 192).